BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reynders N, Abboud D, Baragli A, Noman MZ, Rogister B, Niclou SP, Heveker N, Janji B, Hanson J, Szpakowska M, Chevigné A. The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells 2019;8:E613. [PMID: 31216755 DOI: 10.3390/cells8060613] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 El-tanani M, Platt-higgins A, Lee Y, Al Khatib AO, Haggag Y, Sutherland M, Zhang S, Aljabali AA, Mishra V, Serrano-aroca Á, Tambuwala MM, Rudland PS. Matrix metalloproteinase 2 is a target of the RAN-GTP pathway and mediates migration, invasion and metastasis in human breast cancer. Life Sciences 2022;310:121046. [DOI: 10.1016/j.lfs.2022.121046] [Reference Citation Analysis]
2 Wang X, Zhang Y, Wang S, Ni H, Zhao P, Chen G, Xu B, Yuan L. The role of CXCR3 and its ligands in cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1022688] [Reference Citation Analysis]
3 Valdés N, Cortés M, Barraza F, Reyes-lópez FE, Imarai M. CXCL9-11 chemokines and CXCR3 receptor in teleost fish species. Fish and Shellfish Immunology Reports 2022. [DOI: 10.1016/j.fsirep.2022.100068] [Reference Citation Analysis]
4 Brandt EF, Baues M, Wirtz TH, May J, Fischer P, Beckers A, Schüre B, Sahin H, Trautwein C, Lammers T, Berres M. Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma. IJMS 2022;23:8112. [DOI: 10.3390/ijms23158112] [Reference Citation Analysis]
5 Suresh S, Dix D, Wang L, Blydt‐hansen TD. High urinary CXCL10 /Cr with onset of Burkitt lymphoma in a pediatric kidney transplant recipient. Pediatric Transplantation. [DOI: 10.1111/petr.14354] [Reference Citation Analysis]
6 Bottomley MJ, Harden PN, Wood KJ, Hester J, Issa F. Dampened Inflammatory Signalling and Myeloid-Derived Suppressor-Like Cell Accumulation Reduces Circulating Monocytic HLA-DR Density and May Associate With Malignancy Risk in Long-Term Renal Transplant Recipients. Front Immunol 2022;13:901273. [DOI: 10.3389/fimmu.2022.901273] [Reference Citation Analysis]
7 Hughes DJ, Subesinghe M, Taylor B, Bille A, Spicer J, Papa S, Goh V, Cook GJR. 18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. Radiology 2022;:212481. [PMID: 35762888 DOI: 10.1148/radiol.212481] [Reference Citation Analysis]
8 D'Uonnolo G, Reynders N, Meyrath M, Abboud D, Uchański T, Laeremans T, Volkman BF, Janji B, Hanson J, Szpakowska M, Chevigné A. The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-B. Front Immunol 2022;13:868579. [PMID: 35720349 DOI: 10.3389/fimmu.2022.868579] [Reference Citation Analysis]
9 Satarkar D, Patra C. Evolution, Expression and Functional Analysis of CXCR3 in Neuronal and Cardiovascular Diseases: A Narrative Review. Front Cell Dev Biol 2022;10:882017. [DOI: 10.3389/fcell.2022.882017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xing M, Li J, Magistri P. A New Inflammation-Related Risk Model for Predicting Hepatocellular Carcinoma Prognosis. BioMed Research International 2022;2022:1-33. [DOI: 10.1155/2022/5396128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Jang JH, Park D, Park GS, Kwak DW, Park J, Yu DY, You HJ, Kim JH. Leukotriene B4 receptor-2 contributes to KRAS-driven lung tumor formation by promoting interleukin-6-mediated inflammation. Exp Mol Med 2021;53:1559-68. [PMID: 34635780 DOI: 10.1038/s12276-021-00682-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ehrlich AT, Semache M, Couvineau P, Wojcik S, Kobayashi H, Thelen M, Gross F, Hogue M, Le Gouill C, Darcq E, Bouvier M, Kieffer BL. Ackr3-Venus knock-in mouse lights up brain vasculature. Mol Brain 2021;14:151. [PMID: 34583741 DOI: 10.1186/s13041-021-00862-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kim M, Choi HY, Woo JW, Chung YR, Park SY. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast. Sci Rep 2021;11:18007. [PMID: 34504204 DOI: 10.1038/s41598-021-97390-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Levesque LA, Roy S, Salazar N. CXCR3 Expression and Genome-Wide 3' Splice Site Selection in the TCGA Breast Cancer Cohort. Life (Basel) 2021;11:746. [PMID: 34440489 DOI: 10.3390/life11080746] [Reference Citation Analysis]
15 Clark AM, Heusey HL, Griffith LG, Lauffenburger DA, Wells A. IP-10 (CXCL10) Can Trigger Emergence of Dormant Breast Cancer Cells in a Metastatic Liver Microenvironment. Front Oncol 2021;11:676135. [PMID: 34123844 DOI: 10.3389/fonc.2021.676135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
16 Cinier J, Hubert M, Besson L, Di Roio A, Rodriguez C, Lombardi V, Caux C, Ménétrier-Caux C. Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them? Cancers (Basel) 2021;13:1850. [PMID: 33924428 DOI: 10.3390/cancers13081850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
17 Wang H, Zhou L, Yang Y, Luo B. Screening and identification of key genes in EBV-associated gastric carcinoma based on bioinformatics analysis. Pathol Res Pract 2021;222:153439. [PMID: 34020134 DOI: 10.1016/j.prp.2021.153439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Yan Y, Zheng L, Du Q, Yazdani H, Dong K, Guo Y, Geller DA. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett 2021;506:95-106. [PMID: 33689775 DOI: 10.1016/j.canlet.2021.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
19 Chevigné A, Janji B, Meyrath M, Reynders N, D'Uonnolo G, Uchański T, Xiao M, Berchem G, Ollert M, Kwon YJ, Noman MZ, Szpakowska M. CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6. Cancers (Basel) 2021;13:1054. [PMID: 33801414 DOI: 10.3390/cancers13051054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
20 Korbecki J, Kojder K, Kapczuk P, Kupnicka P, Gawrońska-Szklarz B, Gutowska I, Chlubek D, Baranowska-Bosiacka I. The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature. Int J Mol Sci 2021;22:E843. [PMID: 33467722 DOI: 10.3390/ijms22020843] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 39.0] [Reference Citation Analysis]
21 Wang P, Wang Y, Jiang Y, Li M, Li G, Qiao Q. Immune Cluster and PPI Network Analyses Identified CXCR3 as a Key Node of Immunoregulation in Head and Neck Cancer. Front Oncol 2020;10:564306. [PMID: 33585188 DOI: 10.3389/fonc.2020.564306] [Reference Citation Analysis]
22 Sun H, Fan J, Shang X, Tuohetaerbaike B, Li Y, Lv J, Wang Y, Wang L, Wang J, Ma X. Study on the relationship between CXCR3 and its ligands and tubal tuberculosis. Life Sci 2021;272:119047. [PMID: 33454369 DOI: 10.1016/j.lfs.2021.119047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Huang RZ, Mao M, Zheng J, Liang HQ, Liu FL, Zhou GY, Huang YQ, Zeng FY, Li X. Development of an immune-related gene pairs index for the prognosis analysis of metastatic melanoma. Sci Rep 2021;11:1253. [PMID: 33441929 DOI: 10.1038/s41598-020-80858-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Zhu MX, Wan WL, Hong Y, Wang YF, Dong F, Jing HM. Expression and role of MIG/CXCR3 axis in mantle cell lymphoma. Exp Cell Res 2020;397:112365. [PMID: 33197439 DOI: 10.1016/j.yexcr.2020.112365] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wang X, Zhang J, Zhou G. The CXCL11-CXCR3A axis influences the infiltration of CD274 and IDO1 in oral squamous cell carcinoma. J Oral Pathol Med 2021;50:362-70. [PMID: 33187013 DOI: 10.1111/jop.13130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Itzhaki O, Jacoby E, Nissani A, Levi M, Nagler A, Kubi A, Brezinger K, Brayer H, Zeltzer LA, Rozenbaum M, Vernitsky H, Markel G, Toren A, Avigdor A, Schachter J, Besser MJ. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. J Immunother Cancer 2020;8:e000148. [PMID: 32152221 DOI: 10.1136/jitc-2019-000148] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
27 Yu Y, Zhang H, Ren T, Huang Y, Liang X, Wang W, Niu J, Han Y, Guo W. Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma. J Cell Mol Med 2020;24:11230-42. [PMID: 32820615 DOI: 10.1111/jcmm.15687] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
28 Phan QT, Tan WH, Liu R, Sundaram S, Buettner A, Kneitz S, Cheong B, Vyas H, Mathavan S, Schartl M, Winkler C. Cxcl9l and Cxcr3.2 regulate recruitment of osteoclast progenitors to bone matrix in a medaka osteoporosis model. Proc Natl Acad Sci U S A 2020;117:19276-86. [PMID: 32719141 DOI: 10.1073/pnas.2006093117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
29 Zhu X, Xie X, Zhao Q, Zhang L, Li C, Zhao D. Potential Prognostic Value and Mechanism of Stromal-Immune Signature in Tumor Microenvironment for Stomach Adenocarcinoma. Biomed Res Int 2020;2020:4673153. [PMID: 32685487 DOI: 10.1155/2020/4673153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Morein D, Erlichman N, Ben-Baruch A. Beyond Cell Motility: The Expanding Roles of Chemokines and Their Receptors in Malignancy. Front Immunol. 2020;11:952. [PMID: 32582148 DOI: 10.3389/fimmu.2020.00952] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 22.0] [Reference Citation Analysis]
31 Wu X, Sun A, Yu W, Hong C, Liu Z. CXCL10 mediates breast cancer tamoxifen resistance and promotes estrogen-dependent and independent proliferation. Mol Cell Endocrinol 2020;512:110866. [PMID: 32417506 DOI: 10.1016/j.mce.2020.110866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
32 Bujak JK, Szopa IM, Pingwara R, Kruczyk O, Krzemińska N, Mucha J, Majchrzak-Kuligowska K. The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors. Int J Mol Sci 2020;21:E2292. [PMID: 32225066 DOI: 10.3390/ijms21072292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Ran S, Volk-Draper L. Lymphatic Endothelial Cell Progenitors in the Tumor Microenvironment. Adv Exp Med Biol 2020;1234:87-105. [PMID: 32040857 DOI: 10.1007/978-3-030-37184-5_7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
34 Ornell KJ, Mistretta KS, Newman E, Ralston CQ, Coburn JM. Three-Dimensional, Scaffolded Tumor Model to Study Cell-Driven Microenvironment Effects and Therapeutic Responses. ACS Biomater Sci Eng 2019;5:6742-54. [DOI: 10.1021/acsbiomaterials.9b01267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
35 Paluskievicz CM, Cao X, Abdi R, Zheng P, Liu Y, Bromberg JS. T Regulatory Cells and Priming the Suppressive Tumor Microenvironment. Front Immunol 2019;10:2453. [PMID: 31681327 DOI: 10.3389/fimmu.2019.02453] [Cited by in Crossref: 97] [Cited by in F6Publishing: 102] [Article Influence: 32.3] [Reference Citation Analysis]
36 Zhong X, Chen B, Liu M, Yang Z. The Role of Adaptor Protein CARD9 in Colitis-Associated Cancer. Mol Ther Oncolytics 2019;15:1-6. [PMID: 31650020 DOI: 10.1016/j.omto.2019.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
37 Puchert M, Obst J, Koch C, Zieger K, Engele J. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7. Cytokine 2020;125:154809. [PMID: 31437604 DOI: 10.1016/j.cyto.2019.154809] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]